Menu
About Us
Company Overview
Corporate Culture
Manufacturing Base
MAH
Drug Development to Commercialization
Milestones
Code of Business Ethics
Services
Services
Providing reliable CDMO solutions with excellent quality and professional services
ADC Platform
Overview
ADC R&D Service Platform
Conjugation Process
Development
and Optimization
Drug Product
Formulation and
Lyophilization Process
Analysis Services
Antibody Manufacturing
ADC Drug Substance
Manufacturing
Lyophilized Drug
Product Manufacture
Protein/Antibody Platform
Overview
Cell Culture
Process Development
Purification Process
Development
Drug Product
Formulation and
Lophilization Process
Analysis Services
GMP Manufacturing
Overview
Drug Substance
Manufacturing
Drug Product
Manufacturing
Process Characterization
/Process Validation
Technology Transfer
Overview
Technology Transfer
Quality
Overview
Quality Control
Quality Assurance
Regulatory Affairs
Overview
Service and Advantages
Investor Relations
Company Profile
Corporate Governance
Announcements and Circulars
The Listed Files
Financial Reports and ESG Reports
Company Promotion Materials
Investor Relations Query
Investor Relations Journal
News & Events
News
Events
Media Attention
Partner News
Resources
Technical Articles
Download Center
Join Us
Members of TOT
Join in TOT
Contact Us
EN
繁體
简体
EN
繁體
简体
Home
<
News & Events
News & Events
News
Events
Media Attention
Partner News
2020
2020
2021
2022
2023
2024
2020.11
22
TOT BIOPHARM Unveils Results of Phase III Clinical Trial of TAB008(Bevacizumab Injection)in ESMO ASIA for the First Time
(Hong Kong, 22 November 2020) TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK) announced that the Company has published the phase III clinical research results of its self-developed bevacizumab biosimila…
2020.10
15
TOT BIOPHARM International Company Limited Optimises Company Management Structure to Promote Strategic Development Upgrade
TOT BIOPHARM International Company Limited Optimises Company Management Structureto Promote Strategic Development Upgrade* * *Names Ms. Yeh-Huang, Chun-Yingas Vice Chairman of the BoardAppoints Dr. Liu, Jun as Chief Executive Officer…
2020.08
14
TOT BIOPHARM Announces 2020 Interim Results
TOT BIOPHARM Announces 2020 Interim Results* * *Accelerates Development for UpgradeFocuses on the ADC Platform and Improves Competitiveness (Hong Kong, 13 August 2020) TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock c…
2020.07
23
TOT BIOPHARM Announces First Patient Dosed in Phase III Clinical Trial of ADC Candidate TAA013
(Hong Kong, 23 July 2020) TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK) is pleased to announce that TOT BIOPHARM’s self-developed HER2 targeted antibody drug conjugate (“ADC”) candidate, TAA013, ha…
2020.04
21
TOT BIOPHARM Self-Developed Biological Drug TAB008 (Pusintin®) Meets Primary Endpoint in Phase III Clinical Trial
(Hong Kong, 21April 2020) TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK) is pleased to announce that the randomized Phase III clinical trial of TAB008 (Pusintin®) has recently reached the prede…
2020.04
21
TOT BIOPHARM International Company Limited TOT BIOPHARM Appoints Dr. Liu Jun as Chief Operating Officer
* * * Prepares for Entering Commercial Development Stage Facilitates International Strategic Development Layout (Hong Kong, 21April 2020) TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company;” stock code: 1875.HK) is…
2020.03
19
TOT BIOPHARM International Company Limited TOT BIOPHARM Announces 2019 Annual Results
(Hong Kong, 17 March 2020) TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and
«
1
»
The module is under construction